REFERENCES
- Adachi J., Gomez M., Smith C. C., Sternberg E. M. Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia–myalgia. Arch. Toxicol. 1995; 69: 266–270, [INFOTRIEVE], [CSA]
- Adachi J., Mio T., Ueno Y., Naito T., Nishimura A., Fujiwara S., Sumino K., Tatsuno Y. Identification of four metabolites of 3-(phenylamino) alanine, a constituent of l-tryptophan products implicated in eosinophilia syndrome in rats. Arch. Toxicol. 1994; 68: 500–505, [INFOTRIEVE], [CSA], [CROSSREF]
- Bunag R. D. Validation in awake rats of a tail-cuff method measuring systolic pressure. J. Appl. Physiol. 1973; 34: 279–282, [INFOTRIEVE], [CSA]
- Clauw D. J. Animal models of the eosinophilia-myalgia syndrome. J. Rheumatol. 1996; 23: 93–98, [CSA]
- Crofford L. J., Rader J. I., Dalakas M. C., Hill R. H., Jr., Page S. W., Needham L. L., Brady L. S., Heyes M. P., Wilder R. L., Gold P. W., Illa I., Smith C., Sternberg E. M. L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. J. Clin. Invest. 1990; 86: 1757–1763, [INFOTRIEVE], [CSA]
- DeSchryver-Kecskemeti K., Gramlich T. L., Crofford L. J., Rader J. I., Page S. W., Needham L. L., Hill R. H., Jr., Sternberg E. M. Environmental pathology. Mast cell and eosinophil infiltration in intestinal mucosa of Lewis rats treated with l-tryptophan implicated in human eosinophilia myalgia syndrome. Mod. Pathol 1991; 4: 354–357, [INFOTRIEVE], [CSA]
- Dunnett C. A multiple comparison procedure for comparing several treatments with control. J. Am. Statis. Assoc. 1955; 50: 1096–1121, [CSA], [CROSSREF]
- Hertzman P. A., Blevins W. L., Mayer J., Greenfield B., Ting M., Gleich G. J. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N. Eng. J. Med. 1990; 322: 869–873, [CSA]
- Kilbourne E. M. Eosinophilia-myalgia syndrome: coming to grips with a new illness. Epidemiol. Rev. 1992; 14: 16–36, [INFOTRIEVE], [CSA]
- Klarskov K., Johnson K. L., Benson L. M., Cragun J. D., Gleich G. J., Wrona M., Jiang X. R., Dryhurst G., Naylor S. Structural characterization of a case-implicated contaminant, “Peak X” in commercial preparations of 5-hydroxytryptophan. J. Rheumatol. 2003; 30: 89–95, [INFOTRIEVE], [CSA]
- Lieberman S. Nutraceutical review: 5-hydroxytryptophan. Women's Health Alternative Medicine Report 2000; 2(1)4–6, [CSA]
- Love L. A., Rader J. I., Crofford L. F., Raybourne R. B., Principato M. A., Page S. W., Trucksess M. W., Smith M. J., Dugan E. M., Turner M. L., Zelazowski E., Zelazowski P., Sternberg E. M. Pathological and immunological effects of ingesting l-tryptophan and 1,1'-ethylidenebis in Lewis rats. J. Clin. Invest. 1993; 91: 804–811, [INFOTRIEVE], [CSA]
- Mayeno A. N., Gleich G. J. Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale. Trend Biotechnol. 1994; 12: 346–352, [CSA], [CROSSREF]
- Michelson D., Page S. W., Casey R., Trucksess M. W., Love L. A., Milstein S., Wilson C., Massaquoi S. G., Crofford L. J., Hallett M., Gold P. W., Sternberg E. M. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J. Rheumatol. 1994; 21: 2261–2265, [INFOTRIEVE], [CSA]
- Milburn D. S., Myers C. W. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome. DICP 1991; 25: 1259–1262, [INFOTRIEVE], [CSA]
- Ogawa Y., Adachi J., Tatsuno Y. Accumulation of 1-methyl-tetrahydro-beta-carboline-3-carboxylic acid in blood and organs of rat. Possible causative substance of eosinophilia-myalgia syndrome associated with ingestion of l-tryptophan. Arch. Toxicol. 1993; 67: 290–293, [INFOTRIEVE], [CSA], [CROSSREF]
- Philen R. M., Hill R. H., Jr., Flanders W. D., Caudill S. P., Needham L., Sewell L., Sampson E. J., Falk H., Kilbourne E. M. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia studies of Oregon, New York, and New Mexico. Am. J. Epidemiology 1993; 138: 154–159, [CSA]
- Sato F., Hagiwara Y., Kawase Y. Subchronic toxicity of 3-phenylamino alanine, an impurity in l-tryptophan reported to be associated with eosinophilia-myalgia syndrome. Arch. Toxicol. 1995; 69: 444–449, [INFOTRIEVE], [CSA], [CROSSREF]
- Silver R. M., Ludwicka A., Hampton M., Ohba T., Bingel S. A., Smith T., Harley R. A., Maize J., Heyes M. P. A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan). J. Clin. Invest. 1994; 93: 1473–1480, [INFOTRIEVE], [CSA]
- Williamson B. L., Benson L. M., Tomlinson A. J., Mayeno A N., Gleich G. J., Naylor S. On-line HPLC-tandem mass spectrometry analysis of contaminants of l-tryptophan associated with the onset of the eosinophilia-myalgia syndrome. Toxicol. Lett. 1997; 92: 139–148, [INFOTRIEVE], [CSA], [CROSSREF]
- Williamson B. L., Tomlinson A. J., Hurth K. M., Posada de la Paz M., Gleich G. J., Naylor S. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia-myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome. Biomed. Chromotography 1998; 12: 255–261, [CSA], [CROSSREF]
- Yamaguchi Y., Tsunoda J., Suda T., Miura Y., Shioiri-Nakano K., Kasahara T. Effect of synthesized constituents in the l-tryptophan product on the differentiation of eosinophils and the induction of IL-6: a possible cause of eosinophilia-myalgia syndrome. Biochem. Biophys. Res. Commun. 1991; 178: 1008–1013, [INFOTRIEVE], [CSA], [CROSSREF]